Randomized, Double Blind, Multi Center, Multinational, Placebo Controlled, Single Parallel Escalating Dose Safety and Efficacy Study of ACT017 Used as an Add on Therapy on Top of Standard of Care of Acute Ischemic Stroke
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Glenzocimab (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms ACTIMIS
- Sponsors Acticor Biotech
- 01 Feb 2024 Results published in the Lancet Neurology
- 31 Aug 2023 Post-hoc analysis results assessing the imaging data using Artificial Intelligence (AI) from its phase 1b/2a ACTIMIS study, published in the Media Release.
- 09 May 2022 According to an Acticor Biotech media release, results from this study will be presented at the at the 8th European Stroke Organisation Conference (ESOC), 2022.